Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

International Conference on Harmonization

This article was originally published in The Tan Sheet

Executive Summary

Second draft guidance defining means for electronically submitting regulatory information to FDA published in Federal Register June 14. Guidance includes changes based on comments on first draft, which was published Nov. 28 (1"The Tan Sheet" Dec. 3, 2001, p. 2). Second draft is clearer, has complete glossary of terms, doubles maximum length of a file name to 64 characters, FDA says. Separate guidance, entitled "Q1E Evaluation of Stability Data" and published same day, should instruct on "how to use stability data...to propose a retest period for the drug substance and a shelf life for the drug product." Comments on both are due Aug. 1...

Second draft guidance defining means for electronically submitting regulatory information to FDA published in Federal Register June 14. Guidance includes changes based on comments on first draft, which was published Nov. 28 (1 'The Tan Sheet' Dec. 3, 2001, p. 2). Second draft is clearer, has complete glossary of terms, doubles maximum length of a file name to 64 characters, FDA says. Separate guidance, entitled "Q1E Evaluation of Stability Data" and published same day, should instruct on "how to use stability data...to propose a retest period for the drug substance and a shelf life for the drug product." Comments on both are due Aug. 1....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094153

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel